In 2019, Ma et al. (2019) using bioinformatics and IHC staining methods, discovered that patients with high ACSL5 expression had a shorter PFS than those with low ACSL5 expression, revealing ACSL5 as a potential prognostic marker in pancreatic cancer patients. Here, ACSL5 is linked to pancreatic neoplasm.